The internal thoracic artery (ITA) that differs from coronary artery (CA), rarely develops atherosclerosis. Understanding the mechanism underlying such a difference will help to pave a new way to the prevention and treatment of the disease. We hypothesize herein that the difference in susceptibility to atherosclerosis between CA and ITA is attributable to the heterogeneity of perivascular adipose tissues (PVATs) surrounding these two kinds of arteries, i.e. PVAT-CA and PVAT-ITA. We isolated PVAT from eight patients of coronary heart disease (CHD) and four non-CHD patients. Gene expression patterns were analyzed by using Agilent whole gene expression profile chips. By comparison between PVAT-CA and PVAT-ITA, we identified 2053 differentially expressed genes, of which 1042 were upregulated and 1011 were down-regulated, respectively, in CHD group. KEGG pathway and gene ontology (GO) analysis revealed that those differentially expressed genes related to inflammation, lipid metabolism and myocardial processes were particularly noted in the CHD group, but not in non-CHD. Several selected genes, including interleukin-1β (IL-1β), interleukin-6 (IL-6), Toll-like receptor 2 (TLR2), Toll-interleukin 1 receptor domain containing adaptor protein (TIRAP), serum amyloid A2 (SAA2), and Leptin were validated by real-time PCR analysis. The results showed that the expression levels of IL-1β, IL-6, and Leptin were significantly higher in PVAT-CA than in PVAT-ITA (P = 0.016, 0.021, and 0.018) in CHD patients. Levels of TLR2, TIRAP, and SAA2 expression were also higher in PVAT-CA, however no significant difference was observed (P = 0.054, 0.092, and 0.058). In conclusion, our findings demonstrate differential gene expression patterns between PVAT-CA and PVAT-ITA, revealing a high heterogeneity in PVAT. Particularly, those genes related to inflammation, lipid metabolism and myocardial processes are differentially expressed in PVAT-CA and PVAT-ITA in CHD patients, suggesting an important role of PVAT in the development of coronary atherosclerosis.
Introduction
Adipose tissue plays a vital role in both energy homeostasis and tissue structural support. Adipose tissue is also recognized as a major endocrine organ producing numerous hormones and cytokines [1] . Alterations in either quantity or quality of adipose are often associated with a series of diseases, including obesity, Type 2 diabetes, dyslipidemia, hypertension, and atherosclerosis. Due to a special anatomic and functional connection with cardio-vasculature, the perivascular adipose tissue (PVAT) appears to play a critical role in the pathogenesis of cardiovascular disease. It was reported that PVAT releases a wide variety of cytokines that have significant impacts on vascular biological functions, including smooth muscle cell proliferation [2] , migration [3] , and contraction [4] . PVAT also produces various inflammatory mediators and chemokines, promoting vascular inflammation and atherogenesis [5, 6] .
The PVAT surrounding coronary arteries (PVAT-CA), also known as epicardial adipose tissue, is usually referred to the adipose tissue presenting between epicardial myocardium and visceral pericardium [7] . The main trunk of coronary is placed within PVAT-CA. Recent studies show that PVAT-CA is capable of producing a wide range of cytokines and chemokines, which is critically involved in the development of coronary atherosclerosis [8, 9] . Furthermore, there is strong epidemical and clinical evidence that the changes in PVAT-CA are highly associated with coronary atherosclerosis. PVAT-CA aberration has been regarded as an independent risk factor for atherogenesis [10] [11] [12] .
Strikingly different from coronary artery (CA), internal thoracic artery (ITA) is usually resistant to atherosclerosis, and thus is the most commonly used artery bypass graft in CA bypass grafting (CABG) surgery. Compared to radial artery and great saphenous vein, 10-and 15-year patency rates of ITA bypass graft is, respectively, higher and reached approximately 95%, along with a better survival rate [13] . Understanding the mechanism of ITA resistance to atherogenesis will help us creating a new strategy to prevent and treat the coronary heart disease (CHD). We hypothesize that the difference in susceptibility of CA and ITA to atherosclerosis is attributable to the intrinsic heterogeneity of PVAT surrounding the arteries. To this end, we comparatively analyzed global gene expression profiles of PVAT-CA and PVAT-ITA in both CHD and non-CHD patients. The results provided the first evidence that PVAT-CA and PVAT-ITA are highly heterogeneous, and that the genetic heterogeneity is very likely attributable to the difference between CA and ITA in predisposition to atherosclerosis.
Materials and Methods

Patients
In the current study, eight CHD patients undergoing CABG and four structural heart disease patients (including cardiac valve disease and congenital heart disease) undergoing heart surgery were recruited for global gene expression profiling in PVAT-CA and PVAT-ITA. To exclude a possible bias from patients' sample collection, another four CHD patients undergoing CABG were recruited for real-time RT-PCR validation. All subjects met the following exclusion criteria, including the patients who had a previous cardiac or thoracic surgery; chronic connective diseases such as systemic lupus erythematosus or rheumatoid arthritis; long-term glucocorticoid or immunosuppressive therapy; a history of pericardial disease; severe hepatic or renal dysfunction. The CHD patients were all diagnosed based on digital subtraction angiography evidence of coronary atherosclerosis: stenosis >50% in the left main CA or >75% in other arteries. The four patients with structural heart disease had digital subtraction angiography evidence showing normal coronary arteries without stenosis, and were referred as non-CHD group. Both CHD and non-CHD patients had computed tomography (CT) angiography evidence of normal ITA without stenosis. The clinical characteristics of the patients are detailed in Table 1 . All patients provided written informed consents, and the study was approved by the ethics committee of Zhongshan hospital, Fudan University (Shanghai, China), which is complied with the declaration of Helsinki.
Sample collection
All PVAT samples (average 0.2-0.5 g) were collected from patients during surgery, prior to anticoagulation and establishment of extracorporeal circulation. PVAT-CA samples were obtained from fat around proximal-middle segments of the left anterior descending CA, and PVAT-ITA was taken from adipose tissue surrounding the mid segment of the left ITA. After washing with normal saline and removal of connective tissue and superficial blood vessels, the PVAT samples were frozen immediately in liquid nitrogen and stored at −80°C.
RNA isolation and microarray assays
Total RNA was isolated from each pair of PVAT samples by using TRIZOL (Invitrogen life technologies, Carlsbad, USA). RNA integrity was verified using standard denaturing agarose gel electrophoresis. The quality and amount of the isolated RNA were determined by using a spectrophotometer (NanoDrop ND-1000; Agilent Technologies, Santa Clara, USA). Microarray assays were conducted on 12 pairs of PVAT samples (8 CHD and 4 non-CHD) using Agilent Human 4 × 44 K Gene Expression chips (Agilent Technologies) according to the manufacturer's protocol. Briefly, 1 μg of total RNA from each PVAT sample was linearly amplified and labeled with Cyanine-3-CTP. The labeled cRNAs were purified using RNAeasy Mini Kit (Qiagen, Hilden, Germany). The quantification and specific activity of the labeled cRNAs were measured by NanoDrop ND-1000. After hybridization 
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and washing, the hybridized arrays were scanned using a microarray scanner (Agilent Technologies).
Microarray data analysis
Agilent Feature Extraction software was used to acquire microarray data. The acquired data were analyzed by using GeneSpring GX software (Agilent Technologies). Fold change was calculated as the ratio of labeled signals. Paired t-test was used to compare the gene expression levels for each pair of PVAT-CA and PVAT-ITA. The default threshold of statistical significance was a fold change ≥2.0 or ≤0.5 (P < 0.05). Then, unsupervised hierarchical cluster analysis was conducted to ascertain the differentially expressed genes.
GO, pathways, and protein-protein interaction network analysis
Differently expressed genes were grouped on the basis of the GO consortium (http://www.geneontology.org/). Pathways analysis was conducted based on the databases of KEGG (http://www.genome.jp/ kegg/). Fisher's exact test and the chi square test were used to classify the enrichment of GO and pathway category. The cut-off of P-value that denotes the significance of GO item and pathways was 0.05. Unsupervised hierarchical clustering was performed using Agilent GeneSpring GX software. Protein-protein interaction (PPI) network analysis was performed based on the STRING database.
The network model was generated by the cytoscape application (http://www.cytoscape.org), according to the following information: fold changes in gene expression, PPI, KEGG pathway enrichment, and biological process enrichment of GO.
Real-time RT-PCR
Total RNA was isolated from each pair of PVAT samples as described above. Complementary DNA (cDNA) was generated from 1 μg of total RNA using a high capacity reverse transcription kit with random primers (Applied Biosystems, Foster City, USA). A non-template control for the PCR was also made by omitting reverse transcriptase. The abundance of transcripts was assessed by quantitative real-time PCR on a Rotor-Gene 6000 real-time PCR machine (Qiagen) using SYBR Green (Bio-Rad, Hercules, USA). The expression data for each of interested genes were normalized to a reference gene, beta-actin. Primers used for the RT-PCR are presented in Supplementary Table S1 .
Statistical analysis
Continuous variables of demographic data from Microarrays are presented as the mean ± standard error (SE). Paired t-test was used to compare levels of gene expression for paired samples of PVAT-CA and PVAT-ITA. Student's t-test was performed for the comparison between CHD and non-CHD groups. All analysis was done using SPSS 20.0 statistical software. P-values of <0.05 were considered statistically significant.
Results
Differential gene expression patterns between PVAT-CA and PVAT-ITA in CHD patients
By conducting microarray analysis, we identified 2053 genes that were differentially expressed between PVAT-CA and PVAT-ITA (Fig. 1 ). Among these differentially expressed genes, 1042 genes were up-regulated and 1011 genes were down-regulated in PVAT-CA, compared with in PVAT-ITA. Based on unsupervised clustering analysis, the 1000 most distinguishably expressed genes between PVAT-CA and PVAT-ITA, including 500 up-regulated and 500 down-regulated, are presented in Fig. 2A . Because the analysis was performed without a priori identifying gene groups, it depicts real differences in global gene expression profiles, rather than a result of selection. The data therefore strongly indicate an inherent heterogeneity existing in PVATs, i.e. between PVAT-CA and PVAT-ITA.
To further systematically assess potential connections of the differentially expressed genes to biological functions, we performed GO and KEGG pathway analysis. Notably, among the top 10 significant upregulated groups of biological processes in PVAT-CA, three of them are directly related to inflammation (Fig. 3A) . In keeping with these findings, KEGG pathway analysis reveals that several inflammationrelated pathways were up-regulated in PVAT-CA, including cytokinecytokine receptor interaction, complement and coagulation cascades, and NF-kappa B signaling pathway (Fig. 4A) . Correspondingly, a wide range of inflammation-related genes (such as IL-1β, IL-6, IL-1R, SAA1/2, TLR2, TIRAP, LBP, and so on) were indeed up-regulated in PVAT-CA, compared with PVAT-ITA (Supplementary Table S2 ). Together, these data provide evidence supporting the notion that the inflammation status of PVAT plays a critical role in the pathogenesis of atherosclerosis. It is noted that the most down-regulated biological processes found in PVAT-CA were mainly associated with muscle process and function (Fig. 3B) . Similarly, KEGG pathway analysis shows several cardiomyopathy-related pathways that were significantly down-regulated in PVAT-CA (Fig. 4B) , indicating a close link of PVAT to myocardial lesions. Additionally, the gene profiling shows that fat acid and steroid biosynthesis pathways were up-regulated in PVAT-CA, suggesting distinguishable lipid metabolism status in between PVAT-CA and PVAT-ITA, which further reveals the tissue heterogeneity of PVAT. Moreover, we conducted a PPI network analysis based on the differentially expressed genes between PVAT-CA and PVAT-ITA in CHD group. As shown in Fig. 5A , the hub genes in the network include many inflammation-related genes (such as IL-1β, IL-6, TLR2, and CXCL2), further supporting the role of inflammation on PVAT in atherogenesis.
Differential gene expression patterns between PVAT-CA and PVAT-ITA in non-CHD group
Having shown the differential gene expression profiles between PVAT-CA and PVAT-ITA in CHD patients, we sought to clarify whether the PVAT heterogeneity is a specific feature of CHD. To this end, we performed the same Microarray analysis in non-CHD subjects. A total of 1402 genes were found to be differentially expressed between PVAT-CA and PVAT-ITA in non-CHD patients ( Supplementary Fig. S1 ), indicating the PVAT heterogeneity also existing in non-CHD although the total number of differentially expressed genes found in non-CHD was slightly less than those in CHD group. Among the differentially expressed genes in non-CHD patients, 642 were up-regulated and 760 down-regulated in PVAT-CA compared to PVAT-ITA. The results of unsupervised clustering analysis are presented in Fig. 2B . Interestingly, a remarkable difference between non-CHD and CHD groups was noted in the results of GO and KEGG pathway analysis. GO analysis shows that neither top 10 up-regulated nor top 10 down-regulated biological processes found in non-CHD overlaps with that presented in CHD ( Supplementary Fig. S2 ). The most up-regulated genes by PVAT-CA in non-CHD were mainly related to multicellular organismal process, response to stimulus, nervous system and biological adhesion. Strictly different from CHD, in non-CHD group there are no inflammation-related genes found among the top 10 up-regulated biological processes in PVAT-CA, compared with PVAT-ITA ( Supplementary Fig. S2 ). In addition, the PPI network analysis also exhibited differences between CHD and non-CHD group in the network comparison of PVAT-CA with PVAT-ITA (Fig. 5B) .
Differentially expressed inflammation-related genes between PVAT-CA and PVAT-ITA in CHD patients
Because PVAT has been considered as an important source of inflammatory mediators in atherogenesis [14] , we selected six inflammation-related genes from the microarray assays for further validation. To exclude a possible bias from patients' sample collection, we combined pairs of previous patients' samples from microarray assays, together with four additional pairs of PVAT samples collected from newly reenrolled CHD patients to conduct quantitative real-time RT-PCR analysis. As shown in Fig. 6 , the expression levels of IL-1β, IL-6, and Leptin were significantly higher in PVAT-CA than in PVAT-ITA (P = 0.016, 0.021, and 0.018). Levels of TLR2, TIRAP, and SAA2 expression also tended to be higher in PVAT-CA than ITA, but did not meet a statistical significance (P = 0.054, 0.092, and 0.058). Furthermore, consistent with the data of microarrays, RT-PCR assays showed the difference in expression levels of the six selected genes between PVAT-CA and PVAT-ITA in non-CHD patients (data not shown), indicating a disease-specific feature.
Discussion
The present study depicted a global gene expression profile of PVAT-CA that profoundly distinguishes from that of PVAT-ITA, which, for the first time, reveals the tissue heterogeneity in these two closely related PVAT. Because PVAT plays a critical role in the regulation of vascular biological characteristics and functions, it is ratiocinated that the heterogeneity of PVAT may account for the difference in susceptibility to atherosclerosis between ITA and CA.
Multiple lines of evidence have demonstrated that the general adipose tissues are highly heterogeneous. Adipose tissues in different depots are often derived from various developmental origins and exhibit diverse functional properties, including their roles in metabolism, inflammation, thermogenesis, and angiogenesis [15] . In particular, more attentions have been paid to the heterogeneity among subcutaneous and visceral adipose tissues because of their distinct contributions to metabolic diseases, including atherosclerosis. Epidemiological studies revealed that in comparison with body mass index (BMI), waist-to-hip ratio, or waist circumference (WC), which indicate abdominal visceral fat accumulation, is a more specific risk factor for the development of diabetes, hyperlipidemia and atherosclerosis [16, 17] . Previous studies based on experimental fat transplantation in mice have demonstrated that the diverse effects of subcutaneous and visceral adipose tissue on metabolic homeostasis are not attributed to different anatomical locations but intrinsic heterogeneity among these adipose tissues [18, 19] . Indeed, compared with subcutaneous adipose tissue, visceral adipose tissues isolated from obese subjects display a more pro-inflammatory phenotype, tending to secrete more inflammatory cytokines, including IL-6 [20, 21] , TNFα [22] , complement C3 [22] , and chemokines [23] . However, the mechanism that determines adipose tissue heterogeneity remains to be defined.
PVAT is a sub-depot of visceral adipose tissue which has a vital influence on vascular function [24] . PVAT-CA, lying between the myocardium and the visceral layer of the pericardium, is contiguous to adventitia and myocardium. Besides its unique anatomical feature, PVAT-CA possesses directly functional influences on coronary vascular tone [25] , coronary atherosclerosis [8, 26] , and cardiac arrhythmias [27, 28] . Indeed, the functional property of PVAT-CA is reflected in its gene expression profile, especially with regard to inflammatory reactions, which is markedly distinct from subcutaneous adipose tissue in CHD patients [14] . However, ITA is naturally resistant to atherosclerosis, whether PVAT surrounding ITA exhibits a similar or distinct gene expression profile with PVAT-CA requires to be clarified. To the best of our knowledge, the present study provides the first evidence that the global gene expression profile of PVAT-CA strictly differs from that of PVAT-ITA in humans. Remarkably, a wide range of significantly up-regulated genes in PVAT-CA compared to in PVAT-ITA in CHD patients are related to inflammation and lipid metabolism (Figs. 3A and 4A) . This finding is thus strongly supportive to the current concept that both inflammation and lipid metabolism play critical roles in the pathogenesis of atherosclerosis. It is believed that under certain conditions PVAT can produce various inflammatory mediators through an 'outside-to-inside' signaling model to facilitate vascular inflammation and atherogenesis [29, 30] . Indeed, PVAT isolated from human aorta can release several cytokines and chemokines [31] , by which promoting endothelial inflammation in vitro [29, 32] . Furthermore, significantly higher expression levels of chemokine (e.g., MCP-1) and inflammatory cytokines (e.g., IL-6, IL-1β, and TNFα) in epicardial adipose tissue than in subcutaneous adipose stores were found in patients with established CHD [14] , suggesting that PVAT-CA is an important source of inflammatory mediators that promote the development of atherosclerosis. This notion is further underscored by the present gene expression profiling study, showing that the levels of a wide set of inflammatory mediators are higher in PVAT-CA than in PVAT-ITA in CHD patients. By conducting quantitative real-time PCR analysis, we were able to confirm the six selected inflammation-related genes which are up-regulated in PVAT-CA compared with PVAT-ITA (Fig. 6) . The different gene expression profiles between PVAT-CA and PVAT-ITA, especially those of inflammation and lipid metabolism-related genes, not only depicts an intrinsic heterogeneity of PVAT surrounding different arteries but also further supports a special role of PVAT in the pathogenesis of atherosclerosis.
It is noted in the present study that the genes involved in musclerelated biological processes, including actin-myosin filament sliding, muscle contraction, muscle tissue development, are significantly down-regulated in PVAT-CA compared with those in PVAT-ITA in CHD patients. Previous studies have demonstrated the diverse effects of secretory molecules from adipose tissue on myocardium. For instance, the conditioned medium of subcutaneous adipocytes derived from obese humans has been shown to depress cardiomyocyte contractility [33] . Cardiomyocytes incubated with PVAT-CA isolated from guinea pigs feeding with a high-fat diet resulted in a significant reduction of sarcomere shortening and cytosolic Ca 2+ fluxes [34] . These findings indicate a pathophysiologic connection between PVAT-CA and myocardium. Consistent with this notion, the current study reveals a significant difference in global gene expression related to biological processes of cardiomyocytes and other types of myocytes between PVAT-CA and PVAT-ITA in CHD patients. It is also worth mentioning that ischemic myocardium can produce more inflammatory cytokines [35] , which in turn could influence adjacent adipose tissue. Nevertheless, the differential gene expression patterns related to myocardial processes, together with the genes related to inflammation and lipid metabolism, between PVAT-CA and PVAT-ITA appear to be firmly associated with differential predisposition to atherosclerosis between CA and ITA.
Another important finding in the present study is that although heterogeneity also exists between PVAT-ITA and PVAT-CA in non-CHD patients, the differential gene expression patterns of non-CHD group dramatically differ from that of the CHD group. The most significantly differential expressed genes related to inflammation, lipid metabolism and myocardial processes between PVAT-ITA and PVAT-CA in CHD patients are not present in non-CHD patients. This finding thus indicates that the differential gene expression patterns between PVAT-ITA and PVAT-CA are likely disease-specific. Indeed, such a disease-specific gene expression pattern of PVAT would support the hypothesis that PVAT-CA may play an important role in promoting atherogenesis, whereas PVAT-ITA may prevent it.
In conclusion, the differential gene expression patterns between PVAT-CA and PVAT-ITA reveal a high heterogeneity in PVATs. Such genetic heterogeneity of PVAT is well paralleled with the difference in predisposition to atherosclerosis between CA and ITA. Especially, the heterogeneity in the expression of genes related to inflammation, lipid metabolism and myocardial processes between PVAT-ITA and PVAT-CA in CHD patients suggests a critical role of PVAT in the pathogenesis of coronary atherosclerosis.
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